A61K 38/2207
Gastrins
Official title: {Gastrins; Cholecystokinins [CCK]}
A61K38/2207 (Gastrins) appears on 62 US grants and 121 published applications in this corpus.
Search patents in A61K- Granted patents
- 62
- Published applications
- 121
- Assignees
- 53
- Inventors
- 171
- Latest grant
- 24 Dec 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 3 | 1 |
| 2002 | 0 | 5 |
| 2003 | 2 | 3 |
| 2004 | 2 | 8 |
| 2005 | 1 | 7 |
| 2006 | 5 | 11 |
| 2007 | 2 | 6 |
| 2008 | 2 | 8 |
| 2009 | 2 | 9 |
| 2010 | 6 | 4 |
| 2011 | 2 | 4 |
| 2012 | 1 | 4 |
| 2013 | 1 | 3 |
| 2014 | 2 | 8 |
| 2015 | 2 | 6 |
| 2016 | 5 | 4 |
| 2017 | 2 | 7 |
| 2018 | 2 | 3 |
| 2019 | 4 | 2 |
| 2020 | 0 | 3 |
| 2021 | 3 | 7 |
| 2022 | 1 | 2 |
| 2023 | 2 | 2 |
| 2024 | 1 | 2 |
| 2025 | 0 | 1 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disorders24 Dec 2024US 12,173,063 B2AvenCell Europe GmbH
- Mini-gastrin analogue, in particular for use in CCK2 receptor positive tumour diagnosis and/or treatment11 Apr 2023US 11,623,014 B2Paul Scherrer Institut
- Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders24 Jan 2023US 11,560,426 B2AvenCell Europe GmbH
- Satiation peptides for weight loss and altered taste sensitivity26 Apr 2022US 11,311,633 B2University of Florida Research Foundation, Inc.
- Stable formulations for parenteral injection of peptide drugs27 Apr 2021US 10,987,399 B2Xeris Pharmaceuticals, Inc.
- Combination therapy for treating cancers29 Jan 2026US 2026/0027126 A1Geistlich Pharma AG
- Alteration of nutrient preferences via modulation of nutrient receptors in the gut13 Mar 2025US 2025/0082649 A1The Trustees of Columbia University in the City of New York
- Compositions and methods for islet cell transplants15 Aug 2024US 2024/0269194 A1
- Methods and cck-b receptor agonists for treating tinnitus18 Jul 2024US 2024/0238378 A1City University of Hong Kong
- Compositions and methods for enhancing t cell penetration of tumors and cancers14 Dec 2023US 2023/0398196 A1Cancer Advances Inc.
Most cited
By later US patents
- Use of exendins for the reduction of food intake124US 6,956,026 B2Amylin Pharmaceuticals, Inc. · 2005
- Methods of normalizing metabolic parameters in diabetics101US 5,468,727 ABoard of Regents, The University of Texas System · 1995
- Pharmaceutical compositions containing exendins98US 7,297,761 B2Amylin Pharmaceuticals, Inc. · 2007
- Exendins, exendin agonists, and methods for their use86US 6,989,366 B2Amylin Pharmaceuticals, Inc. · 2006
- Exendins, exendin agonists, and methods for their use85US 7,115,569 B2Amylin Pharmaceuticals, Inc. · 2006